Ernest Flores, MD
Psychiatry · Las Cruces, NMNPI 1154353183
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $17,941 of the $25,178 with a category attached, or 71.3%. 15 manufacturers reported payments, led by Sunovion Pharmaceuticals Inc. at 45.4% of the total. Reporting peaked in 2019 at $14,580 and has fallen 95.6% since, to $642 in 2025. Among psychiatry clinicians in NM with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 423 payments — averaging $59.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sunovion Pharmaceuticals Inc.$11K
- Otsuka America Pharmaceutical, Inc.$11K
- AbbVie$424
- Johnson & Johnson$356
- Teva Pharmaceuticals USA, Inc.$324
- Alkermes, Inc.$321
- plus $1K from 9 others
What the payments were for
- Speaking & faculty fees$17,94171%
- Travel & lodging$1,2225%
- Food & beverage$5,88823%
- Education$1281%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sunovion Pharmaceuticals Inc. | 123 | $11,439 |
| Otsuka America Pharmaceutical, Inc. | 140 | $11,193 |
| AbbVie(2 entities) | 26 | $424 |
| Johnson & Johnson | 30 | $356 |
| Teva Pharmaceuticals USA, Inc. | 23 | $324 |
| Alkermes, Inc. | 17 | $321 |
| Takeda Pharmaceuticals U.S.A., Inc. | 25 | $287 |
| Axsome Therapeutics, Inc. | 8 | $199 |
| Neurocrine Biosciences, Inc. | 10 | $174 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 7 | $145 |
| E.r. Squibb & Sons, L.L.C. | 4 | $132 |
| Lundbeck LLC | 5 | $103 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 3 | $50 |
| Jazz Pharmaceuticals Inc. | 1 | $19 |
| Eisai Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LATUDA$10,228
- ABILIFY MAINTENA$9,029
How this compares
$25,178 in reported general payments places this provider in the 95th percentile of 174 psychiatry providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 122 | $247,948 |
| VraylarCariprazine Hcl | 74 | $118,552 |
| AustedoDeutetrabenazine | 19 | $111,436 |
| Invega SustennaPaliperidone Palmitate | 22 | $52,044 |
| TrintellixVortioxetine Hydrobromide | 22 | $19,900 |
| AuvelityDextromethorphan Hbr/Bupropion | 12 | $10,890 |
| Clozapine | 48 | $5,430 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 76 | $4,870 |
| Divalproex Sodium ErDivalproex Sodium | 31 | $4,001 |
| Olanzapine OdtOlanzapine | 12 | $3,654 |
| Fluvoxamine Maleate | 68 | $3,461 |
| Quetiapine Fumarate | 105 | $3,277 |
| Ziprasidone Hcl | 27 | $3,028 |
| Oxcarbazepine | 27 | $2,967 |
| Divalproex Sodium | 20 | $2,863 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti | $11,193 | $247,948122 claims |
| AbbVieVraylar | $424 | $118,55274 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $324 | $111,43619 claims |
| Johnson & JohnsonInvega Sustenna | $356 | $52,04422 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $287 | $19,90022 claims |
| Axsome Therapeutics, Inc.Auvelity | $199 | $10,89012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 174 psychiatry providers in New Mexico.
Other psychiatry in Las Cruces
- Edgar ChicaLas Cruces$667
- Gabriel HernandezLas Cruces$473
- Patricio EscalonaAlbuquerque$487K
- Mauricio TohenAlbuquerque$160K
- Shiva SharmaAlbuquerque$140K
- Jefferson DavisSanta Fe$53K
- Yvonne HallRio Rancho$11K
- Javier VeraAlbuquerque$8K
- Nancy MartinAlbuquerque$6K
- Reuben SutterAlbuquerque$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.